Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy

by Chrisann Kyi, Claire F. Friedman, Jennifer J. Mueller, Ryma Benayed, Marc Ladanyi, Maria Arcila, Soo Ryum Yang, Martee L. Hensley, Sarah Chiang
Published 2021-08-01

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

by Anastasia Navitski, Duaa H. Al-Rawi, Ying Liu, Maria M. Rubinstein, Claire F. Friedman, Raajit K. Rampal, Diana L. Mandelker, Karen Cadoo, Roisin E. O'Cearbhaill
Published 2021-11-01

Pattern of disease and response to pembrolizumab in recurrent cervical cancer

by Kathryn M. Miller, Olga T. Filippova, Sara A. Hayes, Nadeem R. Abu-Rustum, Carol Aghajanian, Vance Broach, Lora H. Ellenson, Pier Selenica, Elizabeth L. Jewell, Chrisann Kyi, Yuliya Lakhman, Jennifer J. Mueller, Roisin E. O'Cearbhaill, Kay J. Park, Yukio Sonoda, Dmitriy Zamarin, Britta Weigelt, Mario M. Leitao, Jr, Claire F. Friedman
Published 2021-08-01

Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers

by Harini Veeraraghavan, Claire F. Friedman, Deborah F. DeLair, Josip Ninčević, Yuki Himoto, Silvio G. Bruni, Giovanni Cappello, Iva Petkovska, Stephanie Nougaret, Ines Nikolovski, Ahmet Zehir, Nadeem R. Abu-Rustum, Carol Aghajanian, Dmitriy Zamarin, Karen A. Cadoo, Luis A. Diaz, Mario M. Leitao, Vicky Makker, Robert A. Soslow, Jennifer J. Mueller, Britta Weigelt, Yulia Lakhman
Published 2020-10-01